DK0960335T3 - Modulatorer af insulinreceptoraktivitet - Google Patents

Modulatorer af insulinreceptoraktivitet

Info

Publication number
DK0960335T3
DK0960335T3 DK98903515T DK98903515T DK0960335T3 DK 0960335 T3 DK0960335 T3 DK 0960335T3 DK 98903515 T DK98903515 T DK 98903515T DK 98903515 T DK98903515 T DK 98903515T DK 0960335 T3 DK0960335 T3 DK 0960335T3
Authority
DK
Denmark
Prior art keywords
insulin receptor
stimulates
independently
insulin
compounds
Prior art date
Application number
DK98903515T
Other languages
English (en)
Inventor
Hugo O Villar
Richard Sportsman
Wayne R Spevak
Ron A Kohanski
Apparao Satyam
Ryan Koehler
Lawrence M Kauvar
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/784,857 external-priority patent/US5830918A/en
Priority claimed from US08/784,854 external-priority patent/US5851988A/en
Priority claimed from US08/916,088 external-priority patent/US6329431B1/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of DK0960335T3 publication Critical patent/DK0960335T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/62Insulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98903515T 1997-01-15 1998-01-15 Modulatorer af insulinreceptoraktivitet DK0960335T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US78485597A 1997-01-15 1997-01-15
US08/784,857 US5830918A (en) 1997-01-15 1997-01-15 Nonpeptide insulin receptor agonists
US08/784,854 US5851988A (en) 1997-01-15 1997-01-15 Nonpeptide insulin receptor agonists
US82526997A 1997-03-27 1997-03-27
US08/916,088 US6329431B1 (en) 1997-01-15 1997-08-21 Nonpeptide insulin receptor agonists
EP98903515A EP0960335B1 (en) 1997-01-15 1998-01-15 Modulators of insulin receptor activity
PCT/US1998/000801 WO1998032017A2 (en) 1997-01-15 1998-01-15 Modulators of insulin receptor activity

Publications (1)

Publication Number Publication Date
DK0960335T3 true DK0960335T3 (da) 2005-06-20

Family

ID=27542207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98903515T DK0960335T3 (da) 1997-01-15 1998-01-15 Modulatorer af insulinreceptoraktivitet

Country Status (9)

Country Link
EP (1) EP0960335B1 (da)
JP (1) JP2002512685A (da)
AT (1) ATE296446T1 (da)
AU (1) AU6026698A (da)
CA (1) CA2278023A1 (da)
DE (1) DE69830301T2 (da)
DK (1) DK0960335T3 (da)
ES (1) ES2242995T3 (da)
WO (1) WO1998032017A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
CA2343934A1 (en) 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
TWI234557B (en) * 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
WO2000073793A2 (en) * 1999-05-27 2000-12-07 Cecil Yip Identification of compounds modulating insulin receptor activity
FR2796942B1 (fr) * 1999-07-29 2003-02-07 Telik Inc Acides naphtylsulfoniques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
WO2001072771A2 (en) * 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
AU2002245258A1 (en) * 2001-01-12 2002-07-24 Exelixis, Inc. Modulating insulin receptor signaling
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
EP1512396A4 (en) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
JP4743382B2 (ja) * 2002-06-06 2011-08-10 株式会社医薬分子設計研究所 O−置換ヒドロキシアリール誘導体
CA2488367A1 (en) * 2002-06-06 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Antiallergic agents
EP1535609A4 (en) * 2002-06-10 2009-01-07 Inst Med Molecular Design Inc Nf-kb activation inhibitors
EA010835B1 (ru) * 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
DE10323081A1 (de) * 2003-05-22 2004-12-16 Aventis Pharma Deutschland Gmbh Verwendung eines Polypeptides
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023231A1 (en) * 1994-02-28 1995-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
CA2216806A1 (en) * 1995-03-31 1996-10-03 Merck & Co., Inc. Insulin mimetic and enhancer assay

Also Published As

Publication number Publication date
DE69830301D1 (de) 2005-06-30
AU6026698A (en) 1998-08-07
ATE296446T1 (de) 2005-06-15
EP0960335B1 (en) 2005-05-25
EP0960335A2 (en) 1999-12-01
ES2242995T3 (es) 2005-11-16
CA2278023A1 (en) 1998-07-23
WO1998032017A2 (en) 1998-07-23
JP2002512685A (ja) 2002-04-23
DE69830301T2 (de) 2006-02-02
WO1998032017A3 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
DK0960335T3 (da) Modulatorer af insulinreceptoraktivitet
Evans et al. The modulatory actions of FMRFamide and related peptides on locust skeletal muscle
Stanton et al. Epileptiform activity induced by lowering extracellular [Mg2+] in combined hippocampal-entorhinal cortex slices: modulation by receptors for norepinephrine and N-methyl-D-aspartate
Nagy Biophysical processes in invertebrate photoreceptors: recent progress and a critical overview based on Limulus photoreceptors
DE69534485D1 (de) Zyklische struktur-analoga von nervenwachstumfaktor (ngf) und deren verwendung
SE0003984D0 (sv) Adenosin A3-receptormodulatorer
Larsen et al. Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor κB-mediated gene expression in insulin-producing INS-1E cells
DE69724241D1 (de) Gdnf-rezeptor und dessen verwendung
Stansfeld et al. Dendrotoxin-sensitive K+ channels in dorsal root ganglion cells
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
DE3853771D1 (de) Alkylaminopyrimidin-Derivate, Verfahren zu ihrer Herstellung und diese als aktive Bestandteile enthaltende Insektizide, Akarizide und Fungizide.
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
Syková Modulation of spinal cord transmission by changes in extracellular K+ activity and extracellular volume
Warnick et al. Pumiliotoxin-C and synthetic analogues. A new class of nicotinic antagonists.
TR199901157T2 (xx) �nsektisid bile�imleri ve y�ntemleri
AR015685A1 (es) Compuesto de heteroarilcarboxamida o una sal fisiologicamente aceptable del mismo y su uso para la preparacion de una composicion farmaceutica
Meisheri et al. Reserpine-induced supersensitivity to the cardiac effects of agonists
Evans Phenyliminoimidazolidine derivatives activate both OCTOPAMINE1 and OCTOPAMINE2 receptor subtypes in locust skeletal muscle
DE69626387D1 (de) Antagonisten von humanem interleukin-6, welche zur bindung mit gp 130 unfähig sind und ihre verwendung in der herstellung von pharmazeutische zusammensetzungen
Pasztor et al. The modulatory effects of serotonin, neuropeptide F1 and proctolin on the receptor muscles of the lobster abdominal stretch receptor and their exoskeletal muscle homologues
DK0788512T3 (da) Proinsulinpeptidforbindelser til detektion og behandling af Type I-diabetes
DE3685060D1 (de) Verwendung von kojic-saeure oder ihres beta-cyclodextrin-einschlusskomplexes zur praevention von elastosis.
Wang et al. Modulatory effects of myomodulin on the excitability and membrane currents in Retzius cells of the leech
Durussel et al. Cation-and peptide-binding properties of human calmodulin-like skin protein
WO2006102653A3 (en) Methods and compositions for treating insulin resistance and obesity-induced diseases